- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00659659
A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma
October 9, 2012 updated by: MedImmune LLC
A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Effects of MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Airway Eosinophils in Adults With Atopic Asthma
Evaluate the safety and tolerability of MEDI-563 in adults with asthma and the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Evaluate the safety and tolerability of MEDI-563 in adults with atopic asthma; and evaluate the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies 28 days after completion of dosing in adults with atopic asthma.
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Quebec, Canada, G1V4G5
- Research Site
-
-
Alberta
-
Calgary, Alberta, Canada, T2N4N1
- Research Site
-
-
British Columbia
-
Vancouver,, British Columbia, Canada
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N3Z5
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 2P4
- Research Site
-
-
-
-
Colorado
-
Denver, Colorado, United States, 80206
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Research Site
-
-
Texas
-
Galveston, Texas, United States, 77555-0561
- Research Site
-
Houston, Texas, United States, 77030
- Research Site
-
Houston, Texas, United States
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female adults, 18 through 65 years of age at time of randomization;
- Written informed consent obtained from the subject prior to beginning study procedures or receipt of any study medication;
- Previously documented diagnosis of asthma of ≥ 1 year duration, based on episodic symptoms of airflow obstruction; post-bronchodilator reversibility of airflow obstruction ≥ 12% (in USA only - if subject does not achieve this during screening, proof of ≥12% reversibility within 1 year of randomization is acceptable) or proof of a positive response to a methacholine challenge during screening with prior approval from MedImmune (in USA only - within 1 year of randomization is acceptable) as represented by a provoking concentration of methacholine to cause a 20% fall in FEV1 (PC20) < 8 mg/ml [American Thoracic Society (ATS), 2000)]; and exclusion of alternative pulmonary diagnoses (eg, cystic fibrosis, COPD);
- Asthma symptoms are adequately controlled on a therapeutic regimen that has not changed in the last 4 weeks prior to Study Day 0, and the subject is willing to maintain the same therapeutic regimen and doses from the time of screening to the time of the first follow-up bronchoscopy with airway mucosal biopsies (Study Day 28 for Cohort 1; Study Day 84 for Cohort 2);
- Pre-bronchodilator FEV1/forced vital capacity (FVC) ratio that is below the age-adjusted normal limit as defined by the 2007 National Heart Lung and Blood Institute Asthma guidelines (Appendix D) and post-bronchodilator FEV1 ≥ 65% at screening;
- Must have ≥ 2.5% eosinophils in sputum;
- Have had no hospitalizations due to asthma in the last year prior to screening;
- Women of childbearing potential, unless surgically sterile or at least 1 year post-menopausal, must use 2 effective methods of avoiding pregnancy
- Able to complete the follow-up period as required by the protocol;
- Willing to forego other forms of experimental treatment and study procedures during the study and during an 84-day period after the last dose of study drug;
- Able to provide spirometric readings that meet ATS standards
Exclusion Criteria:
- Participation in any previous MEDI-563 clinical study;
- Known history of allergy or adverse reactions to any component of the study drug formulation;
- Lung disease other than asthma (eg, COPD, cystic fibrosis, eosinophilic pneumonia);
- Current use of any systemic or inhaled immunosuppressive drugs [oral (up to a maximum dose of 10 mg/day or 20 mg every other day) and inhaled corticosteroids are allowed if dose has been stable for at least 4 weeks prior to study drug administration on Study Day 0].
- Current use of any β-blocker (eg, propranolol);
- Acute illnesses or evidence of clinically significant active infection, such as fever ≥ 38.0ºC (100.5ºF) at screening and through the time of the study drug administration on Study Day 0;
- Receipt of any investigational drug therapy, intravenous immunoglobulin (IVIG), or monoclonal therapy (eg, Xolair) within 30 days or within 5-half lives prior to study drug administration on Study Day 0 through End of Study/Study Termination (Study Day 84 for Cohort 1 or Study Day 140 for Cohort 2);
- Pregnancy (women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to study drug administration on Study Day 0);
- Breastfeeding or lactating;
- History of alcohol or drug abuse < 1 year prior to Study Day 0;
- History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy > 1 year prior to Study Day 0;
- History of a previous episode of active TB or a positive TB skin test without completion of an appropriate course of treatment;
- A history of coagulation disorders that would contraindicate mucosal biopsies;
- History of immunodeficiency or infection with HIV-1, HIV-2, or hepatitis A, B, or C virus;
- History of use of tobacco products within 2 years of baseline (Study Day 0) or history of smoking ≥ 10 pack-years;
- Elective surgery planned from the time of screening through first follow-up bronchoscopy with airway mucosal biopsies (Study Day 28 or Study Day 84, as applicable);
- Evidence of any systemic disease or respiratory disease (other than asthma), history of any disease, or any finding upon physical examination, screening laboratory test, chest X-ray (CXR), or ECG that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study results;
- Any employee of the research site who is involved with the conduct of the study;
- History of lidocaine allergy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 4
Placebo
|
Placebo SC
|
Placebo Comparator: 5
Placebo
|
Placebo as a single IV infusion (Certain number of subjects)
|
Experimental: 1
MEDI-563
|
1.0 mg/kg IV: MEDI-563
100 mg, 200 mg SC
|
Experimental: 2
MEDI-563
|
1.0 mg/kg IV: MEDI-563
100 mg, 200 mg SC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the safety and tolerability of MEDI-563 in adults with atopic asthma and evaluate the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies 28 days after completion of dosing in adults with atopic asthma.
Time Frame: Study Day 84 or Day 140 - (dose-driven)
|
Study Day 84 or Day 140 - (dose-driven)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the pharmacokinetics (PK) of MEDI-563 in adults with atopic asthma, and evaluate the immunogenicity (IM) of MEDI-563 in adults with atopic asthma.
Time Frame: Day 84 or 140
|
Day 84 or 140
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: David Gossage, M.D., MBA, MedImmune LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
January 1, 2011
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
April 11, 2008
First Submitted That Met QC Criteria
April 11, 2008
First Posted (Estimate)
April 16, 2008
Study Record Updates
Last Update Posted (Estimate)
October 10, 2012
Last Update Submitted That Met QC Criteria
October 9, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MI-CP166
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on MEDI-563
-
MedImmune LLCCompletedAsthmaUnited States, Canada
-
MedImmune LLCCompleted
-
AstraZenecaCompletedAsthmaUnited States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; AstraZenecaCompletedSevere Prednisone Dependent Eosinophilic AsthmaCanada
-
MedImmune LLCAstraZenecaCompletedPulmonary Disease, Chronic ObstructiveUnited States, Poland, Spain, United Kingdom, Denmark, Canada, Germany
-
MedImmune LLCCompleted
-
MedImmune LLCMedImmune LtdCompletedAsthmaUnited States, Brazil, Bulgaria, Mexico, Peru, Poland, Russian Federation, Argentina, Canada, Colombia
-
MedImmune LLCAstraZenecaTerminatedLupus Erythematosus, SystemicUnited States, Mexico, Peru, South Africa, Canada
-
MedImmune LLCCompletedCancer | Graft-Versus-Host DiseaseUnited States
-
MedImmune LLCTerminatedLymphoma | Leukemia | CancerUnited States